Neurocrine Biosciences has handed back two discovery-stage gene therapy programs to Voyager Therapeutics, although the companies’ wider central-nervous-system-focused collaboration remains on track.
- Translational potential of TRACER-derived AAV capsids demonstrated by data across multiple species (murine, porcine, multiple NHPs, human cells) and receptor binding - - Preclinical safety and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results